menu
    • menu
    [{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series A Financing","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnCusp Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnCusp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"Phase I","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OnCusp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OnCusp Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by OnCusp Therapeutics

    Menu

    OnCusp Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    OnCusp Therapeutics

    U.S.A arrow
    BePharma
    Not Confirmed

    OnCusp Therapeutics

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CUSP06

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    OnCusp Gains FDA Fast Track for CUSP06 in Platinum-Resistant Ovarian Cancer

    Details : CUSP06 is a CDH6-directed antibody-drug conjugate (ADC) being developed by OnCusp Therapeutics for the treatment of platinum-resistant ovarian cancer and other advanced solid tumors.

    Product Name : CUSP06

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    February 12, 2025

    Lead Product(s) : CUSP06

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    OnCusp Therapeutics

    U.S.A arrow
    BePharma
    Not Confirmed

    OnCusp Therapeutics

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CUSP06

    Therapeutic Area : Oncology

    Study Phase : IND Enabling

    Sponsor : Organovo Holdings

    Deal Size : $100.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    OnCusp Raises $100 Million in Oversubscribed Series A Financing for Cancer Assets

    Details : The proceeds will be used to advance CUSP06, the company's antibody drug conjugate (ADC) targeting CDH6 against cancer, toward clinical proof-of-concept.

    Product Name : CUSP06

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Undisclosed

    April 01, 2024

    Lead Product(s) : CUSP06

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Sponsor : Organovo Holdings

    Deal Size : $100.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    OnCusp Therapeutics

    U.S.A arrow
    BePharma
    Not Confirmed

    OnCusp Therapeutics

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CUSP06

    Therapeutic Area : Oncology

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer ...

    Details : CUSP06 is a highly differentiated, global second-in-class cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC) designed for the treatment of Ovarian Cancer and Other Advanced Solid Tumors.

    Product Name : CUSP06

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    August 15, 2023

    Lead Product(s) : CUSP06

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth